Considering the enormity of the problem in terms of women infected per year, urogenital infections receive far too little attention from scientists, government funding agencies, and the ...

BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) and the developer of ReviTM, a patient-centric ...

GSK plc. (GSK, GSK.L) announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class ...

Initial results from a recent Phase 1 clinical trial indicate that the experimental vaccine CTH522 could be a crucial tool ...

Data from a phase 3 trial show the antibiotic gepotidacin had a 92.6% microbiologic success rate and was non-inferior to the ...

April 17 is International Bat Appreciation Day! In celebration of these sometimes unsung nocturnal pollinators, a new study ...

Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine ...

In this setting, two infectious diseases are relevant whose diagnosis is not always easy: urogenital schistosomiasis and urogenital tuberculosis. A study in apparently healthy minor refugees from ...

Barrigel should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and ...

Gregor Reid G, Bruce AW. Could Probiotics Be an Option for Treating and Preventing Urogenital Infections? MedGenMed 3(4), 2001 [formerly published in Medscape Women's Health eJournal 6(5), 2001].

a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults. The results are based on a primary endpoint of ...